LLY
Eli Lilly and Company
LLY has the edge over ZETA overall, supported by lower modeled downside and stronger valuation.
ZETA
Zeta Global Holdings Corp.
ZETA's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ZETA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Healthy |
ZETA's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ZETA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 29x | $37.27 | — |
| Current | 248x | $37.27 | — |
| Cheap | N/A | N/A | N/A |
| Fair | N/A | N/A | N/A |
| Expensive | N/A | N/A | N/A |
Historical ranges are pointers, not guarantees.
ZETA has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ZETA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for ZETA, with profitability improving. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
ZETA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.27 | +748% |
| Q3 2026 | $0.15 | +$0.23 |
| Q2 2026 | -$0.01 | +$0.14 |
| Q1 2026 | -$0.10 | +$0.15 |
| Q4 2025 | -$0.14 | +$0.24 |
| Q3 2025 | -$0.08 | +$0.61 |
| Q2 2025 | -$0.15 | +$0.72 |
| Q1 2025 | -$0.25 | +$0.80 |
| Q4 2024 | -$0.38 | +$0.82 |
ZETA has returned to profit: it earned $0.15 per share over the past year, after losing money the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ZETA on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ZETA on profitability, with a higher operating margin.
ZETA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $492.7M | +46% |
| Q2 2026 | $442.8M | +44% |
| Q1 2026 | $396.3M | +50% |
| Q4 2025 | $394.6M | +25% |
| Q3 2025 | $337.2M | +26% |
| Q2 2025 | $308.4M | +35% |
| Q1 2025 | $264.4M | +36% |
| Q4 2024 | $314.7M | +50% |
ZETA's revenue has grown year over year every quarter since early 2021: $493M last quarter, up 46% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.3% | +6.7 points |
| Q2 2026 | 3.8% | +5.5 points |
| Q1 2026 | -4.8% | +1.3 points |
| Q4 2025 | 4.5% | +2.3 points |
| Q3 2025 | 2.6% | +7.2 points |
| Q2 2025 | -1.7% | +10 points |
| Q1 2025 | -6.1% | +12 points |
| Q4 2024 | 2.2% | +17 points |
ZETA's operating margin was 9.3% last quarter, up 6.7 points from the same quarter a year ago, near the top of its range since 2020.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
ZETA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $88.3M | +68% |
| Q2 2026 | $64.4M | +62% |
| Q1 2026 | $46.7M | +46% |
| Q4 2025 | $60.9M | +72% |
| Q3 2025 | $52.4M | +78% |
| Q2 2025 | $39.7M | +63% |
| Q1 2025 | $32.1M | +70% |
| Q4 2024 | $35.4M | +66% |
ZETA has the edge over LLY on cash flow, with more consistent year-over-year improvement.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ZETA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ZETA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.1% | +8M shares |
| 1 year | +19% | +42.2M shares |
| 3 years | +67% | +107M shares |
| 5 years | +417% | +213M shares |
| Available history | +712% | +232M shares |
ZETA has 265M diluted shares, up 19% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ZETA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.7x | Net Cash |
| Q2 2026 | -1.0x | Net Cash |
| Q1 2026 | -1.1x | Net Cash |
| Q4 2025 | -1.6x | Net Cash |
| Q3 2025 | -3.0x | Net Cash |
| Q2 2025 | -4.5x | Net Cash |
| Q1 2025 | -14.1x | Net Cash |
ZETA has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ZETA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 70.3 | Overbought |
| Stochastic | 75.8 | Neutral |
ZETA's weekly RSI is 70 (overbought) and its Stochastic is 76 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ZETA PE vs Technology Sector
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
ZETA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $32.6 | 15% above |
| 20 week MA | $28.6 | 30% above |
| 50 week MA | $22.6 | 65% above |
| 100 week MA | $19.7 | 89% above |
| 200 week MA | $16.7 | 123% above |
ZETA is in an uptrend: it's above all five of its weekly moving averages, and 123% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
ZETA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $8.27 | $8.40 | +1.6% |
| 2022 | $8.40 | $8.21 | -2.3% |
| 2023 | $8.21 | $8.82 | +7.4% |
| 2024 | $8.82 | $17.7 | +100% |
| 2025 | $17.7 | $20.7 | +17% |
| 2026 YTD | $20.7 | $37.3 | +80% |
ZETA has the edge over LLY on returns for 2026, with the stronger performance.